Japanese Patent 7,908,389, Registered 10 August 2026: What Toshiba and AOI Biosciences Claim for Allosteric Site Prediction, and What Quantum-Inspired SQBM+ Actually Runs On

Quentir Medicine Monitor

Evidence-based insights for quantum medicine.

On 3 September 2026 Toshiba Corporation and AOI Biosciences announced that a patent the two companies had filed together was registered in Japan on 10 August 2026. It covers an allosteric pathway prediction device: software that reads a protein's three-dimensional structure and predicts the internal routes leading to pockets that sit away from the site where the protein does its work.

Three parts of that announcement carry different weights. Japanese Patent 7,908,389 is a legal instrument whose protection runs to its granted claims in Japan, which is a separate question from whether the method finds sites nobody had found before. The supporting evidence offered in the release is one figure, accuracy of 80 percent or higher on already-known sites, reported without a definition of accuracy, a benchmark set or a paper behind it. And the optimization engine at the center of the work, Toshiba's SQBM+, is described as quantum-inspired, a term that here means the solver runs on ordinary classical computers and uses no qubits.